Related Experiment Videos
[Phenotypic analysis of myeloma cells]
Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 1, 1995
Summary
Two-color flow cytometry using CD38, VLA-5, MPC-1, CD19, and CD56 antibodies aids in diagnosing bone marrow plasmacytosis. This method distinguishes normal from malignant plasma cells and identifies myeloma cell differentiation stages.
Area of Science:
- Immunology
- Hematology
- Cell Biology
Context:
- Accurate differential diagnosis of bone marrow plasmacytosis is crucial for patient management.
- Distinguishing between normal plasma cells, malignant myeloma cells, benign monoclonal gammopathy, and polyclonal gammopathy requires precise cellular identification.
- Understanding the differentiation stages of myeloma cells can inform treatment strategies.
Purpose:
- To evaluate the utility of 2-color phenotypic analysis for diagnosing bone marrow plasmacytosis.
- To differentiate between normal (polyclonal) and malignant (monoclonal) plasma cells using specific antibody markers.
- To characterize the differentiation stages (immature, intermediate, mature) of myeloma cells.
Summary:
- CD38 expression identifies plasma cells within the CD38strong positive (CD38++) fraction.
- Adhesion molecule expression (VLA-5, MPC-1) defines immature (VLA-5-MPC-1-), intermediate (VLA-5-MPC-1+), and mature (VLA-5+ MPC-1+) plasma cells.
- CD19 and CD56 antibody analysis distinguishes normal (CD19+ CD56-) from malignant (CD19- CD56+) plasma cells.
Impact:
- This 2-color phenotypic analysis provides a valuable tool for the differential diagnosis of bone marrow plasmacytosis, including myeloma.
- It aids in distinguishing benign monoclonal gammopathy and polyclonal gammopathy from multiple myeloma.
- The method enhances the understanding of myeloma cell differentiation, potentially guiding therapeutic approaches.